Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen: Zarxio Lawsuit 'Poor Vehicle' To Interpret BPCIA

This article was originally published in Scrip

Executive Summary

The US Supreme Court should decline Sandoz Inc.'s request to review a ruling by the US Court of Appeals for the Federal Circuit involving the Biologics Price Competition and Innovation Act (BPCIA) because the case is a "poor vehicle" for the high-court's first interpretation of the 2010 biosimilars law, Amgen Inc. argued in a new brief.

Advertisement
Advertisement
UsernamePublicRestriction

Register